Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1990 Mar;28(3):458–462. doi: 10.1128/jcm.28.3.458-462.1990

Antibody responses to protein A in patients with Staphylococcus aureus bacteremia and endocarditis.

D P Greenberg 1, A S Bayer 1, D Turner 1, J I Ward 1
PMCID: PMC269644  PMID: 2324274

Abstract

To assess the significance of antibody to Staphylococcus aureus protein A (SpA) in human sera, we developed a modified enzyme-linked immunosorbent assay (ELISA). SpA antibody levels in 23 patients with S. aureus endocarditis (IE), 21 patients with non-IE S. aureus bacteremia, and 33 controls were measured. Geometric mean levels of antibody to SpA were significantly higher in S. aureus IE patients (134 ELISA units [EU]) than in uninfected controls (52 EU; P less than 0.01). Also, a significantly greater proportion of S. aureus IE patients (12 of 23) and S. aureus non-IE bacteremia patients (11 of 21) had antibody levels greater than an arbitrary threshold of 100 EU compared with uninfected controls (0 of 23; P less than or equal to 0.001). However, no significant differences in geometric mean SpA antibody levels between the bacteremic patients with and without IE were noted. The sensitivity and specificity of this ELISA to distinguish patients with S. aureus IE from those with non-IE bacteremia were low (52 and 48%, respectively). There was a significant association between SpA antibody levels and either immunoglobulin G or immunoglobulin M teichoic acid antibody levels (r = 0.406, P less than 0.05; r = 0.571, P = 0.002, respectively). For patients from whom multiple sera were available (13 IE and 5 non-IE patients), SpA antibody levels were measured over time and showed a wide temporal variation of immune responses. We conclude that antibody responses to SpA can be measured in many patients with invasive S. aureus disease but that the levels are of insufficient sensitivity or specificity to be of clinical use as a diagnostic or prognostic test.

Full text

PDF
458

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bayer A. S., Lam K., Ginzton L., Norman D. C., Chiu C. Y., Ward J. I. Staphylococcus aureus bacteremia. Clinical, serologic, and echocardiographic findings in patients with and without endocarditis. Arch Intern Med. 1987 Mar;147(3):457–462. doi: 10.1001/archinte.147.3.457. [DOI] [PubMed] [Google Scholar]
  2. Christensson B., Espersen F., Hedström S. A., Kronvall G. Solid-phase radioimmunoassay of immunoglobulin G antibodies to Staphylococcus aureus peptidoglycan in patients with staphylococcal infections. Acta Pathol Microbiol Immunol Scand B. 1983 Dec;91(6):401–406. doi: 10.1111/j.1699-0463.1983.tb00067.x. [DOI] [PubMed] [Google Scholar]
  3. Dossett J. H., Kronvall G., Williams R. C., Jr, Quie P. G. Antiphagocytic effects of staphylococcal protein A. J Immunol. 1969 Dec;103(6):1405–1410. [PubMed] [Google Scholar]
  4. Espersen F., Hedström S. A. Precipitating antibodies against Staphylococcus aureus in serum from patients with staphylococcal septicaemia, investigated by means of quantitative immunoelectrophoretic methods. Acta Pathol Microbiol Scand B. 1981 Aug;89(4):261–266. doi: 10.1111/j.1699-0463.1981.tb00186_89b.x. [DOI] [PubMed] [Google Scholar]
  5. Forsgren A. Protein A from Staphylococcus aureus. 8. Production of protein A by bacterial and L-forms of S. aureus. Acta Pathol Microbiol Scand. 1969;75(3):481–490. [PubMed] [Google Scholar]
  6. Forsgren A. Significance of protein a production by staphylococci. Infect Immun. 1970 Nov;2(5):672–673. doi: 10.1128/iai.2.5.672-673.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Forsgren A., Sjöquist J. "Protein A" from S. aureus. I. Pseudo-immune reaction with human gamma-globulin. J Immunol. 1966 Dec;97(6):822–827. [PubMed] [Google Scholar]
  8. Greenberg D. P., Bayer A. S., Cheung A. L., Ward J. I. Protective efficacy of protein A-specific antibody against bacteremic infection due to Staphylococcus aureus in an infant rat model. Infect Immun. 1989 Apr;57(4):1113–1118. doi: 10.1128/iai.57.4.1113-1118.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Mudd S., Gladstone G. P., Lenhart N. A. The antigenicity in man of staphlylococcal leucocidin toxoid, with notes on therapeutic immunization in chronic osteomyelits. Br J Exp Pathol. 1965 Aug;46(4):455–472. [PMC free article] [PubMed] [Google Scholar]
  10. Peterson P. K., Verhoef J., Sabath L. D., Quie P. G. Effect of protein A on staphylococcal opsonization. Infect Immun. 1977 Mar;15(3):760–764. doi: 10.1128/iai.15.3.760-764.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Stålenheim G., Götze O., Cooper N. R., Sjöquist J., Müller-Eberhard H. J. Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus. Immunochemistry. 1973 Aug;10(8):501–507. doi: 10.1016/0019-2791(73)90221-8. [DOI] [PubMed] [Google Scholar]
  12. Tenenbaum M. J., Archer G. L. Prognostic value of teichoic acid antibodies in Staphylococcus aureus bacteremia: a reassessment. South Med J. 1980 Feb;73(2):140-3, 149. doi: 10.1097/00007611-198002000-00006. [DOI] [PubMed] [Google Scholar]
  13. Verbrugh H. A., Peters R., Rozenberg-Arska M., Peterson P. K., Verhoef J. Antibodies to cell wall peptidoglycan of Staphylococcus aureus in patients with serious staphylococcal infections. J Infect Dis. 1981 Jul;144(1):1–9. doi: 10.1093/infdis/144.1.1. [DOI] [PubMed] [Google Scholar]
  14. Zollinger W. D., Boslego J. W. A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies. J Immunol Methods. 1981;46(2):129–140. doi: 10.1016/0022-1759(81)90130-7. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES